Introduction to Hereditary Haemorrhagic Telangiectasia (HHT) Care Pathway in Ireland

Hereditary Haemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare genetic disorder characterised by abnormal blood vessel formation, leading to recurrent nosebleeds, telangiectases (small blood vessel malformations), and potentially life-threatening arteriovenous malformations (AVMs) in various organs.

In Ireland, HHT affects a small but significant portion of the population, necessitating a specialised and comprehensive approach to care.

The HHT Care Pathway in Ireland aims to streamline and optimise the management of patients with HHT by providing a structured framework for healthcare professionals involved in their care. This pathway encompasses various aspects of HHT management, including diagnosis, multidisciplinary assessment, treatment, and long-term follow-up, with a focus on delivering personalised care tailored to each patient’s needs.

In summary, the HHT Care Pathway in Ireland provides a structured and coordinated approach to the management of patients with this complex genetic disorder. By facilitating early diagnosis, personalised treatment and ongoing support, this pathway aims to improve outcomes and enhance the overall well-being of individuals living with HHT in Ireland.


You can read our Care Pathway for HHT which has been created by HSE National Rare Diseases Office and approved by our National Centre for HHT,  in Mercy University Hospital, Cork.